锁定加压钢板治疗股骨转子间骨折21例临床分析

目的:观察锁定加压钢板治疗股骨转子间骨折的疗效.方法:应用锁定加压钢板治疗股骨转子间骨折21例.结果:21例患者3～ 6个月骨折均愈合,未出现断钉、内固定松动等并发症,无明显髋内翻和下肢短缩畸形;Harris评分为优11例,良8例,可2例.结论:锁定加压钢板治疗股骨转子间骨折具有容易安装、固定可靠、手术时间短、出血量少、髋关节功能恢复优良率高等特点,是一种有效的手术方法.     

缺血预处理介导神经保护的分子机制

大量动物实验证实,缺血预处理可产生强大的器官保护作用,但动物实验向临床试验转化的进展和结果不尽如人意.对缺血预处理介导的神经保护的分子机制进行研究,寻找可转化到临床的安全且有效的预处理诱导方式,对于提高卒中和手术患者神经组织对缺血缺氧的耐受力,实现安全和有效的神经保护具有重要意义.文章从预处理活化受体、线粒体、转录因子和蛋白激酶等方面对缺血预处理介导神经保护的分子机制进行了综述.     

无线定位技术在门诊信息系统中的应用研究

分析几种无线定位技术的优缺点,介绍其在门诊信息系统中的应用,包括电子导医、无线门诊输液系统、医疗设备与资产管理、药品定位及自动化库存管理、人员定位、呼叫系统以及输液病人体征检测等.     

Effects of Electroacupuncture on Arrhythmia of Model Rabbits in Different Functional States

目的 探讨电针对不同机能状态家兔心律失常的影响.方法 通过20、25、30 μg/k3种不同剂量的乌头碱,将59只家兔诱发出不同程度的心律失常,以心律失常开始时间和持续时间为指标,对比观察电针对不同机能状态家兔心律失常影响的差异.结果 3种剂量的乌头碱能诱发出家兔3种不同程度的心律失常,三者间差异具有统计学意义；电针对20 μg/kg乌头碱诱发的家兔心律失常的减缓作用明显优于30 μg/kg组.结论 针刺效应与机体异常状态的程度有关,在本实验中,针刺对抗中等程度的家兔心律失常效果最好.     

Botulinum injection for the treatment of acute esotropia resulting from complete acute abducens nerve palsy

PurposeThe objective of this study was to investigate the effectiveness of botulinum toxin A (BTX-A) injections in the treatment of acute esotropia resulting from complete acute abducens nerve palsy.MethodsFifteen patients treated for complete acute abducens nerve palsy in our clinic were retrospectively reviewed. All patients who experienced an onset within 3 months and who were treated with early subtenon BTX-A injections at the ipsilateral medial rectus muscle without electromyography (EMG) guidance were included in this study. Responses and complications were recorded during a follow-up of at least 6 months.ResultsThirteen patients who had trauma and two patients who had brain tumor that caused their abducens nerve palsy were enrolled. Overall, six patients (40%) had full recovery and two patients (13%) had partial recovery, but the residual esotropia could be tolerated with prism correction in an average of 14.6 weeks. Seven patients (47%) received strabismus surgery afterward. Patients who did not respond well to early BTX-A injections at the 1-week interval were prone to subsequent surgical intervention (p = 0.026). Three eyes (20%) had transient subconjunctival hemorrhage following the subtenon space injection; no other complications were found after the treatment.ConclusionBTX-A offers patients with complete abducens palsy a possible better chance to regain binocular vision and indicates whether additional surgical interventions are needed for these patients. We also discovered that the subtenon space injection of BTX-A without EMG guidance was a safe, time-saving, and simple technique.     

Progranulin correlated with rapid progressive interstitial lung disease in dermatomyositis with anti-melanoma differentiation-associated gene 5 antibody

Clinical Rheumatology - This study aimed to detect the expression of progranulin (PGRN) and elucidate associations with clinical features in dermatomyositis (DM) patients with anti-melanoma...     

An Update on the Clinical Development of Proprotein Convertase Subtilisin Kexin 9 Inhibitors,Novel Therapeutic Agents for Lowering Low‐Density Lipoprotein Cholesterol

Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays an essential role in the degradation of low‐density lipoprotein C (LDL‐C) receptors, and PCSK9 inhibitors have recently emerged as a potential treatment option to reduce LDL‐C. Our paper reviewed the current available Phase II clinical trials of PCSK9 inhibitors for the treatment of dyslipidemia. A second objective of this review was to evaluate the potential clinical role of PCSK9 inhibitors in the management of dyslipidemia. Studies evaluating the efficacy and safety of any PCSK9 inhibitors in patients with dyslipidemia were included. The monoclonal antibodies REGN727/SAR236553 and AMG145 have the most published clinical data. Seven phase II trials were retrieved that evaluated the efficacy and safety of REGN727/SAR236553 or AMG145 in patients with either hypercholesterolemia or heterozygous familial hypercholesterolemia (HeFH). These two agents significantly decreased LDL‐C levels either as monotherapy or in combination with other lipid‐lowering agents. REGN727/SAR236553 and AMG145 have been well tolerated. The ongoing phase III trials of these two agents are summarized. REGN727/SAR236553 and AMG145 have demonstrated the potential to further decrease LDL‐C levels when added to conventional lipid‐lowering therapy. Morbidity and mortality data are required to define their roles in clinical practice.